Last reviewed · How we verify
Tenofovir Alafenamide Fumarate tablets
Tenofovir Alafenamide Fumarate tablets is a Small molecule drug developed by Southeast University, China. It is currently FDA-approved. Also known as: TAF, Vemlidy.
Tenofovir Alafenamide Fumarate tablets are a small molecule inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. They are used to treat conditions such as HIV-1-infection and Acquired Immunodeficiency Syndrome.
At a glance
| Generic name | Tenofovir Alafenamide Fumarate tablets |
|---|---|
| Also known as | TAF, Vemlidy |
| Sponsor | Southeast University, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children (PHASE2)
- Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV (EARLY_PHASE1)
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (PHASE2, PHASE3)
- Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PHASE3)
- Pre-Exposure Prophylaxis for Transgender Women in the US and South America (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir Alafenamide Fumarate tablets CI brief — competitive landscape report
- Tenofovir Alafenamide Fumarate tablets updates RSS · CI watch RSS
- Southeast University, China portfolio CI
Frequently asked questions about Tenofovir Alafenamide Fumarate tablets
What is Tenofovir Alafenamide Fumarate tablets?
Who makes Tenofovir Alafenamide Fumarate tablets?
Is Tenofovir Alafenamide Fumarate tablets also known as anything else?
What development phase is Tenofovir Alafenamide Fumarate tablets in?
Related
- Manufacturer: Southeast University, China — full pipeline
- Also known as: TAF, Vemlidy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing